



Substitute for forms 1449A/PTO & 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

 ATTORNEY'S DKT NO.
029395-017

 APPLICATION NO.
09/658,621

 APPLICANT
Joyce TAYLOR-PAPADMITRIOU et.al.

 FILING DATE
September 8, 2000

 GROUP
1644

RECEIVED

SEP 04 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Pei-Xiang XIANG et al., "Synthetic Peptides Reactive with Anti-Human Milk Fat Globule Membrane Monoclonal Antibodies", Cancer Research, Vol. 50, No. 1, 1 January 1990, pp. 89-96, The American Association of Immunologists, Bethesda, MD
	Vasso APOSTOLOPOULOS et al., "Anti-MUC1 Antibodies React Directly with MUC1 Peptides Presented by Class I H2 and HLA Molecules", The Journal of Immunology, Vol. 161, 1998, pp. 767-775, The American Association of Immunologists, Bethesda, MD
	Nieves DOMENECH et al., "Identification of an HLA-A11-Restricted Epitope from the Tandem Repeat Domain of the Epithelial Tumor Antigen Mucin", The Journal of Immunology, Vol. 155, 1995, pp. 4766-4774, The American Association of Immunologists, Bethesda, MD
	Vasso APOSTOLOPOULOS et al., "MUC1 Peptide Epitopes Associated with Five Different H-2 Class I Molecules", European Journal Of Immunology, Vol. 27, October 1997, pp. 2579-2587, Weinheim, Verlag Chemie GmbH, Germany
	Isao NISHIMORI et al., "N-Acetylgalactosamine Glycosylation of MUC1 Tandem Repeat Peptides by Pancreatic Tumor Cell Extracts", Cancer Research, Vol. 54, 15 July 1994, pp. 3738-3744, The American Association of Immunologists, Bethesda, MD
	Lior CARMON et al., "Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in D ^b -/-X ^β 2 Microglobulin (β2m) Null Mice Transgenic For A Chimeric HLA-A2.1/D ^b -β2 Microglobulin Single Chain", International Journal of Cancer, Vol. 85, No. 3, 1 February 2000, Wiley-Liss, New York, NY
	Peter BROSSART et al., "Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", Blood, Vol. 93, No. 12, 15 June 1999, Grune & Stratton, New York
	Babita AGRAWAL et al., "The Anti-MUC1 Monoclonal Antibody VCP8 Can Be Used to Isolate and Identify Putative Major Histocompatibility Complex Class I Associated Amine Acid", Cancer Research, Vol. 58, November 1998, pp. 5151-5156, The American Association of Immunologists, Bethesda, MD
	Janice L. KAM et al., "MUC1 Synthetic Peptide Inhibition of Intercellular Adhesion Molecule-1 and MUC1 Binding Requires Six Tandem Repeats", Cancer Research, Vol. 58, December 1998, pp. 5577-5581, The American Association of Immunologists, Bethesda, MD
	Geoffrey A. PIETERSZ et al., "Definition of MHC-Restricted CTL Epitopes from Non-Variable Number of Tandem Repeat Sequence of MUC1", Vaccine, Vol. 18, No. 19, April 2000, pp. 2059-2071, Butterworths, Guildford, Surrey, UK
	Babita AGRAWAL et al., "In Vitro Induction of MUC-1 Peptide-Specific Type 1 T Lymphocyte and Cytotoxic T Lymphocyte Responses from Healthy Multiparous Donors", Cancer Research, Vol. 58, 15 November 1998, pp. 5151-5156, The American Association of Immunologists, Bethesda, MD
	Vasso APOSTOLOPOULOS et al., "Induction of HLA-A2-Restricted CTLs to the Mucin 1 Human Breast Cancer Antigen", The Journal of Immunology, Vol. 159, 1997, pp. 5211-5218, The American Association of Immunologists, Bethesda, MD

Examiner Signature	Date Considered
-----------------------	--------------------

 EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.